Rationale of combination chemotherapy based on preclinical experiments.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001375:Azaguanine / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy; D003561:Cytarabine / Q000627:therapeutic use; D004357:Drug Synergism; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007167:Immunotherapy; D007939:Leukemia L1210 / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000601:surgery / Q000628:therapy; D013882:Thiosemicarbazones / Q000627:therapeutic use; D013997:Time Factors
D000970:Antineoplastic Agents; D013882:Thiosemicarbazones; D003561:Cytarabine; D001375:Azaguanine; D006918:Hydroxyurea